Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Andrew Hantel, MD


Medical Oncology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Instructor of Medicine, Harvard Medical School
  • Hospitalist, Department of Medical Oncology, Dana-Farber Cancer Institute
  • Postdoctoral Fellow, Division of Population Science, Dana-Farber Cancer Institute

Clinical Interests

  • Hospital Medicine

Contact Information

Bio

Dr. Hantel graduated from Loyola University Chicago Stritch School of Medicine in 2013 and received internal medicine residency and hematology/oncology and medical ethics fellowship training at The University of Chicago. He is a hospitalist in Medical Oncology and is a postdoctoral fellow in the Division of Population Science (PI: Dr. Gregory Abel).

Board Certification:

  • Internal Medicine
  • Medical Oncology

Fellowship:

  • The University of Chicago, Hematology/Medical Oncology
  • The University of Chicago, Medical Ethics

Residency:

  • University of Chicago, Internal Medicine

Medical School:

  • Loyola University Chicago

Research

Dr. Hantel is a postdoctoral fellow in the lab of Dr. Gregory Abel, where he investigates the mechanisms and effects of scarce resource allocation on hematology/oncology patients.



Dr. Hantel’s research focuses on investigating and advancing ethical issues of scarce resource allocation in hematology/oncology through patient-centered health services research methods. His research seeks to incorporate patient and physician perspectives into topical ethical dilemmas, thereby informing practice and policy. His recent work employs normative, qualitative, and quantitative approaches to evaluate aspects of the ongoing medication shortage crisis in U.S. hospitals. This work demonstrated the high burden of shortages and medication rationing in hospitals and was published in JAMA Internal Medicine. He is currently examining oncology patient perspectives on shortage management and how different medication shortage allocation models can improve the ability for hospitals to provide needed medications when supplies are limited.



His other research focus is triage and personnel shortages, which are an increasing and understudied problem in subspecialized hematology/oncology care. As advanced care becomes more complex, adequately trained personnel to deliver such care is an increasing barrier to patient access. Dr. Hantel has published a normative ethical framework in the Journal of Medical Ethics evaluating how to justly allocate cellular therapeutics as personnel shortages worsen. His current work is focused on evaluating the current cellular therapy workforce, modeling growth and potential personnel shortages, and working with key stakeholders to improve equitable patient access to care.

Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical Trials. Blood Adv. 2021 Sep 02.
View in: PubMed

Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 Jul 12.
View in: PubMed

Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematol. 2021 04; 8(4):e246-e248.
View in: PubMed

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
View in: PubMed

US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer. JAMA Oncol. 2021 02 01; 7(2):199-205.
View in: PubMed

Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 Mar 15; 127(6):875-883.
View in: PubMed

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175.
View in: PubMed

A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and Their Preferences for How Shortages Should Be Managed. JCO Oncol Pract. 2020 10; 16(10):e1098-e1111.
View in: PubMed

An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncol. 2020 04 01; 6(4):469-470.
View in: PubMed

A Cross-Sectional Survey of Medical Trainee Experiences During Medication Shortages. J Grad Med Educ. 2020 Feb; 12(1):38-43.
View in: PubMed

Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
View in: PubMed

Practical allocation system for the distribution of specialised care during cellular therapy access scarcity. J Med Ethics. 2019 08; 45(8):532-537.
View in: PubMed

Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists. JAMA Intern Med. 2019 05 01; 179(5):710-711.
View in: PubMed

Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.
View in: PubMed

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73.
View in: PubMed

Creating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse. J Clin Oncol. 2018 09 01; 36(25):2575-2577.
View in: PubMed

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.
View in: PubMed

A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med. 2018 06; 21(6):846-849.
View in: PubMed

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
View in: PubMed

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.
View in: PubMed

No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911.
View in: PubMed

Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use. Ann Intern Med. 2015 Jan 20; 162(2):141-2.
View in: PubMed

A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
View in: PubMed

A protocol and ethical framework for the distribution of rationed chemotherapy. J Clin Ethics. 2014; 25(2):102-15.
View in: PubMed

Analysis of very elderly (=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012 Jan; 156(2):196-204.
View in: PubMed

Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res. 1990 Jun 01; 50(11):3284-8.
View in: PubMed

Listeriosis in the setting of malignant disease. Changing issues in an unusual infection. Cancer. 1989 Jul 15; 64(2):516-20.
View in: PubMed

Clinical and pharmacologic reappraisal of dichloromethotrexate. J Natl Cancer Inst. 1988 Dec 07; 80(19):1547-53.
View in: PubMed

Location

Dana Building
450 Brookline Ave.
Boston, MA 02215
Get Directions

Top